Kennedy Capital Management, Inc. Repligen Corp Transaction History

Kennedy Capital Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$160.42 - $256.21 $177,264 - $283,112	-1,105 Reduced 33.87%	2,157 $404,000
Q2 2022 Aug 10, 2022	SELL	$140.68 - $188.02 $844 - $1,128	-6 Reduced 0.18%	3,262 $530,000
Q1 2022 May 16, 2022	BUY	$161.19 - $257.96 $142,330 - $227,778	883 Added 37.02%	3,268 $615,000
Q4 2021 Feb 14, 2022	SELL	$247.59 - $304.47 $50,260 - $61,807	-203 Reduced 7.84%	2,385 $632,000
Q3 2021 Nov 15, 2021	SELL	$194.77 - $324.21 $8,569 - $14,265	-44 Reduced 1.67%	2,588 $748,000
Q2 2021 Aug 16, 2021	BUY	$165.87 - $220.95 $19,738 - $26,293	119 Added 4.74%	2,632 $525,000
Q1 2021 May 14, 2021	BUY	$180.37 - $226.26 $453,269 - $568,591	2,513 New	2,513 $489,000

482

56.3M

251K

458K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $7.6B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.